🟢 Immunitybio is trading 4.4% up in pre-market as biotech ETF XBI rises 2.27%

Immunitybio is trading at $8.06 (+4.40%), primarily on biotech-sector strength.

• Biotech ETF XBI is up 2.27% pre-market after positive Merck-Moderna cancer-vaccine trial results.
• No fresh company-specific announcement was identified for August 19, 2026.
• Recent ImmunityBio developments, including record second-quarter net product revenue of $50.7 million, were reported earlier in August.